August 1, 2013

Q2 2013: Last Quarter with Significant Negative Impact from the Patent Cliff

 

Q2 2013: Last Quarter with Significant Negative Impact from the Patent Cliff

Commenting on the Group’s performance in Q2 2013, Sanofi Chief Executive Officer, Christopher A. Viehbacher said, “The second quarter was a difficult quarter. As expected, this was the last quarter with a tough comparison to the prior year due to the residual impact of the patent cliff. Sales were also affected by our business in Brazil(3) and commercial underperformance in certain business areas. However, sales growth of 7.7%(4) of our growth platforms(5) in the first half of 2013 continues to demonstrate the value of Sanofi’s integrated business model. In addition, we keep on making strong progress in delivering a growing portfolio of high potential R&D assets, as highlighted by the multiple clinical and regulatory milestones reached in the second quarter of 2013. We continue to expect to return to growth in the second half of 2013.